These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33904110)

  • 41. New concepts regarding finite oral antiviral therapy for HBeAg-negative chronic hepatitis B.
    Papatheodoridi M; Papatheodoridis G
    J Hepatol; 2021 Dec; 75(6):1495-1496. PubMed ID: 34171438
    [No Abstract]   [Full Text] [Related]  

  • 42. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
    Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
    Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice.
    Cuenca-Gómez JÁ; Lozano-Serrano AB; Cabezas-Fernández MT; Soriano-Pérez MJ; Vázquez-Villegas J; Estévez-Escobar M; Cabeza-Barrera I; Salas-Coronas J
    BMC Infect Dis; 2018 Nov; 18(1):568. PubMed ID: 30428845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
    Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Clinical effect and safety of 144-week treatment with entecavir capsules in treatment-naïve HBeAg-positive patients with chronic hepatitis B].
    Cai DC; Pan C; Yu WH; Dang SS; Li J; Wu SM; Jiang N; Wang MR; Zhang ZH; Lin F; Xin SJ; Yang YF; Shen BS; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2017 Aug; 25(8):597-600. PubMed ID: 29056009
    [No Abstract]   [Full Text] [Related]  

  • 48. Safety and efficacy of two-step peginterferon α-2a treatment in patients of chronic hepatitis B with acute exacerbation.
    Chen CC; Wang PC; Chang HW; Chen CF
    J Viral Hepat; 2012 Mar; 19(3):161-72. PubMed ID: 22329370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Management of HBeAg negative chronic hepatitis B].
    Jia JD
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):539. PubMed ID: 16042896
    [No Abstract]   [Full Text] [Related]  

  • 50. Treatment of HBeAg-positive hepatitis B with peginterferon and lamivudine.
    Song K; Rajvanshi P
    N Engl J Med; 2005 Oct; 353(15):1630-1; author reply 1630-1. PubMed ID: 16221792
    [No Abstract]   [Full Text] [Related]  

  • 51. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of Serum IFN- and IL-5 Levels in Response to Entecavir Therapy in Patients with Chronic Hepatitis B Virus Infection.
    Badary TM; ElBadawy O; Agban MN; Kamel S; Sadek A
    Egypt J Immunol; 2018 Jan; 25(1):93-103. PubMed ID: 30243001
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection.
    Cho JH; Lim JH; Park GY; Kim JS; Kang YJ; Kwon O; Choi JY; Park SH; Kim YL; Kim HK; Huh S; Kim CD
    Transpl Infect Dis; 2014 Apr; 16(2):295-303. PubMed ID: 24628837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.
    Nagata N; Kagawa T; Hirose S; Arase Y; Tsuruya K; Anzai K; Shiraishi K; Mine T
    BMC Gastroenterol; 2016 Mar; 16():38. PubMed ID: 26987437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of hepatitis flare on HBeAg loss was effective mainly in the first year of Nucleot(s)ide therapy in chronic hepatitis B.
    Peng CW; Jeng WJ; Chien RN; Liaw YF
    J Viral Hepat; 2021 Mar; 28(3):475-483. PubMed ID: 33274536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues.
    Sonneveld MJ; van Oord GW; van Campenhout MJ; De Man RA; Janssen HLA; de Knegt RJ; Boonstra A; van der Eijk AA
    J Viral Hepat; 2019 Jul; 26(7):828-834. PubMed ID: 30896057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
    Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
    Papatheodoridis GV
    Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [HBsAg seroconversion after entecavir therapy for 7 years following a poor response to interferon-α 2b monotherapy in a HBeAg-negative patient with chronic hepatitis B].
    Li TY; Chen YP
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Aug; 36(9):1303-1304. PubMed ID: 27687670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.